Powered by

Home Funding News Binny Bansal-Backed RISA Labs Raises $11 Mn Funding

Binny Bansal-Backed RISA Labs Raises $11 Mn Funding

RISA Labs, a Healthcare AI startup has raised $11.1 Mn (over INR 100 Cr) in a Series A funding round co-led by US-based VC firms Cencora Ventures and Optum Ventures.

By Jitendra swami
New Update
Binny Bansal-Backed RISA Labs Raises $11 Mn Funding

RISA Labs, a Healthcare AI startup has raised $11.1 Mn (over INR 100 Cr) in a Series A funding round co-led by US-based VC firms Cencora Ventures and Optum Ventures.

The round also saw participation from Oncology Ventures, Z21 Ventures and John Simon, cofounder of General Catalyst, through his Ventureforgood entity.

The fresh capital will be used to expand the distribution of RISA’s system to cancer clinics, health systems, specialty pharmacies, and infusion networks across the US.

Read also- Pee Safe raises $32 million in round from OrbiMed

“In our vision for oncology, there are two sides to every patient’s journey: getting them on the right therapy faster, and deepening our understanding of the disease for the next patient through data,” said Jaggi, CEO of RISA Labs.

“As oncology therapies increase in number and complexity, tools that streamline operations and enable faster access to treatment become vital,” said Jason Dinger, senior vice president at Cencora.

Founded in June 2024 by Kshitij Jaggi and Kumar Shivang, Palo Alto-based RISA’s AI-powered console, BOSS, simplifies complex oncology workflows by breaking them into smaller tasks managed by AI agents. The AI operating system is purpose-built for the realities of cancer care, addressing complex payer rules, multi-drug regimens, and disease-specific requirements.

The AI integrated into RISA’s offering is designed to tackle the core mathematical challenges in modern cancer care.

Advertisment

The startup said that RISA is already live at some of the largest oncology practices in the US. In one such unit, approximately 80% of administrative staff time has been freed up, denial rates have been reduced by up to 40% and first-pass approval rates have reached 97.8%.

Looking ahead to 2026, the San Francisco-based startup plans to deepen its focus on oncology by partnering with ecosystem leaders to expand AI-driven workflows across the full continuum of cancer care.

Want to go deeper into the world of startups and entrepreneurship? Check out these categories on VIESTORIES:

Latest Business and Startup NewsDiscover Funding Trends and Stories Shaping Indian Startups.

Startup Funding NewsYour Gateway to Every Funding Update.

Latest Startup NewsStay updated with the latest startup news and trends. Your go-to source for startup ecosystem updates.

banner

Startup StoriesDiscover inspiring tales of startups overcoming challenges, and achieving success.

Advertisment